Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome
NCT ID: NCT00938756
Last Updated: 2010-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying cerebrospinal fluid samples in diagnosing carcinomatous meningitis in patients with cancer or meningeal syndrome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study in Leptomeningeal Metastases of Breast Cancer
NCT03252912
Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
NCT02948751
Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.
NCT03974204
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
NCT00033397
Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT05130840
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF) using automated immuno-enzymatic methods.
Secondary
* Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.
* Assess favorability of intrathecal production of CA 15-3.
* Determine threshold interpretations of CA 15-3 levels in CSF.
OUTLINE: This is a multicenter study.
Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of carcinomatous meningitis undergo cerebrospinal MRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnostic laboratory biomarker analysis
immunoenzyme technique
magnetic resonance imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets 1 of the following criteria:
* Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis
* Other type of cancer with evidence suggestive of carcinomatous meningitis
* Meningeal syndrome without context of cancer
PATIENT CHARACTERISTICS:
* No other prior cancers
* Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
* No prior intrathecal treatment
* At least 4 weeks since prior interferon
* No concurrent participation in another clinical trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Le Rhun
Role: PRINCIPAL_INVESTIGATOR
Centre Oscar Lambret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Oscar Lambret
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Emilie Le Rhun
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COL-MENINCA
Identifier Type: -
Identifier Source: secondary_id
COL-IDRCB-2008-A00185-50
Identifier Type: -
Identifier Source: secondary_id
COL-0801
Identifier Type: -
Identifier Source: secondary_id
INCA-RECF0807
Identifier Type: -
Identifier Source: secondary_id
CDR0000633542
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.